Filgotinib in Crohn’s Disease: JAK Is Back [PDF]
Gastroenterology, 2017 Silvio, Danese +2 more
openaire +2 more sources
Exploring the interactions of JAK inhibitor and S1P receptor modulator drugs with the human gut microbiome: Implications for colonic drug delivery and inflammatory bowel disease [PDF]
The gut microbiota is a complex ecosystem, home to hundreds of bacterial species and a vast repository of enzymes capable of metabolising a wide range of pharmaceuticals.
Abdalla, Youssef +7 more
core
Filgotinib per al tractament de l’artritis reumatoide
, 2023 Filgotinib; Rheumatoid arthritis; Janus ...
openaire +1 more source
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team. [PDF]
Intest ResHong SM +19 more
europepmc +1 more source
Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis. [PDF]
Front PharmacolWu H +6 more
europepmc +1 more source
Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis
, 2023 Arnott, Ian Dr +9 more
core +3 more sources
The JAK1-STAT1 signaling pathway triggers inflammation responses in chronic obstructive sleep apnea rat model. [PDF]
PLoS OneYang L, He J.
europepmc +1 more source
Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study. [PDF]
Crohns Colitis 360Matsuoka K +4 more
europepmc +1 more source
Real-World Comparative Efficacy and Safety of Upadacitinib, Tofacitinib, and Filgotinib in Patients With Ulcerative Colitis. [PDF]
CureusAhmad F +5 more
europepmc +1 more source
Long-term clinical outcomes with filgotinib in ulcerative colitis: 12-month results from the FILGUITO study. [PDF]
World J GastroenterolCaballero-Mateos AM +13 more
europepmc +1 more source